NEURO HIV/AIDS Objectives
description
Transcript of NEURO HIV/AIDS Objectives
![Page 1: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/1.jpg)
NEURO HIV/AIDS Objectives
1. Review the various etiological agents that cause neurological disorders
2. Give key points when taking a history 3. Describe the clinical presentation of each
disorder 4. List the recommended diagnostics and
common findings for each disorder 5. Understand the treatment and
management of neurological disorders 6. Discuss preventive measures
![Page 2: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/2.jpg)
Overview
Reported incidence Reported incidence ((16%16% to to 72%72%) ) of neurological of neurological abnormalities varies greatlyabnormalities varies greatly.. A wide range of neurological manifestations is A wide range of neurological manifestations is reportedreported: : cognitive defectscognitive defects, , focal deficitsfocal deficits, , painful feet painful feet syndromesyndrome, , encephalopathyencephalopathy.. Pathogens arePathogens are::
the HIV itselfthe HIV itself several several Ois Ois & & neoplasmsneoplasms drugsdrugs
While 5-year survival after the toxo episode was 8% in 1990-1993, it had climbed to 30 % by 1994-1996. This rate has risen to approximately 80 % since 1997 in countries where HAART is readily available.
![Page 3: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/3.jpg)
1. Epidemiology of HIV/AIDS
INTERNATIONAL CENTRE FOR EYE HEALTH TEACHING SET NO.8 HIV/AIDS
Adults and Children Estimated to be Living with HIV/AIDS (June 2000)
Source UNAIDS / WHO
![Page 4: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/4.jpg)
![Page 5: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/5.jpg)
HIV and AIDS IN CANADA •58,929 from November 1985 up to June 30, 2005. •4,200 New HIV cases every year! • 33% HIV-positive Canadians don't know they are infected! • $36 million funding CIDA gave to HIV/AIDS initiatives in 2001-02 Source: Public Health Agency of Canada
![Page 6: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/6.jpg)
Acute HIV Infection
12%Neuro Sx32%Diarrhea12%Thrush54%Myalgia/arthralgia13%Wt loss70%Rash14%HSM70%Pharyngitis27%N/V74%LAD32%Headache96%Fever
CDC 2002
Neuro: meningoencepalitis or aseptic meningitis; peripheral neuropathy or radiculopathy; facial palsy, Guillain-Barre syndrome; brachial neuritis; cognitive impairment or psychosis
![Page 7: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/7.jpg)
• >12% of Primo Infection & “seroconversion” have neuro Sx! • Problems & Special Cases
• The "diagnostic window“ • Needle-stick injury or other occupational exposure
![Page 8: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/8.jpg)
2. Human Immunodeficiency Virus (HIV) and AIDS
INTERNATIONAL CENTRE FOR EYE HEALTH TEACHING SET NO.8 HIV/AIDS
![Page 9: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/9.jpg)
Major Pathogens
Protozoal infection Toxoplasma Gondii (toxoplasmosis) Mycobacterial infection M. tuberculosis (TB meningitis) Bacterial Strep pneumoniae, Neisseria meningitis (bacterial meningitis) Fungal infection Cryptococcus neoformans (cryptococcal meningitis) Viral infection Cytomegalovirus (CMV) Other: Progressive multifocal leukoencephalopathy (PML)
Primary CNS lymphoma HIV-associated dementia (HAD) Painful sensory and motor peripheral neuropathies Neurosyphilis
1515% % of patients have concurrent of patients have concurrent ((>>22) ) AIDSAIDS--related related CNS CNS OIsOIs..
![Page 10: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/10.jpg)
ProtozoalProtozoal infection infection: : ToxoplasmaToxoplasma gondii gondii ((toxoplasmosistoxoplasmosis)) Presenting Signs and SymptomsPresenting Signs and Symptoms
reactivation of a latent infection
Usually: acute neurological syndrome Clinical symptoms may evolve quickly • Focal neurological deficits • Headache (severe, localized) • Seizures • personality changes, cognitive disorders • Fever • Confusion • Myalgia • Arthralgia
HE
![Page 11: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/11.jpg)
> 85% seropositive for T. gondii antibodies.
PCR (blood or CSF) has little relevance
CSF values • Normal: 20-30% • Protein: 10-150/ml • WBC: 0-40 (monos)
An HIV-infected individual presenting with typical signs
and symptoms and normal cerebrospinal fluid findings should be put on treatment for toxoplasmosis. Response to therapy (within 2 weeks) then confirms the diagnosis.
Diagnostics
tachyzoites within pseudocysts (Grocott's silver)
![Page 12: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/12.jpg)
•• 1 1//3 3 solitarysolitary, , 11//3 3 several several ((22--55) ) or or 11//3 3 multiplemultiple; ; deep or deep or juxtacorticaljuxtacortical lesions wlesions w//oedema oedema ; ; big big or smallor small..
•• 90%90% smooth smooth, , peripheral ring peripheral ring enhancementenhancement
••The more lesions there The more lesions there areare,, the more likely thethe more likely the
immunostaining
![Page 13: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/13.jpg)
![Page 14: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/14.jpg)
![Page 15: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/15.jpg)
![Page 16: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/16.jpg)
Unique FeaturesUnique Features, , CaveatsCaveats
One of the most common HIV-related neurological complications without HAART If patient does not receive maintenance therapy, disease will recur. Usually occurs when CD4<100 Check blood picture regularly for toxicity. Leukopenia, thrombocytopenia and rash are common. Folinic (not folic!) acid reduces the risk of myelosuppression. During treatment, patients should maintain a high fluid intake and urine output. Empirical treatment may be diagnostic, but any lesion that failed to improve after 2-4 weeks biopsy needed! Rare: chorioretinitis (vs CMV)
![Page 17: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/17.jpg)
Mycobacterial Infection: M. tuberculosis (TB Meningitis)
Presenting Signs and Symptoms
Most common feature of extrapulmonary TB is cervical lymphadenopathy, but every organ can be involved.
Gradual onset of headache and decreased consciousness
• Low grade evening fevers • Night sweats, Weight loss • Neck stiffness, Kernig’s, etc • Cranial nerve palsies (III & IV !)
![Page 18: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/18.jpg)
Tuberculoma (rare)
CSF Values
• Normal: 5-10% • Protein: High (40mg/dl-100 mg/dl) • WBC: 5-2000 (average is 60-70% monos) • Glucose: low (<20 mg/dl) • AFB smear : 20% (negative if “no bacteria” after 8 weeks) • PCR sensitivity:95% specificity 40-77%
Diagnostics
![Page 19: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/19.jpg)
Unique featuresUnique features, , CaveatsCaveats
CD4<350, and if <100 circulating CD4 cells/µl, the risk of mortality is high. MAC is rare until <50 CD4s
MTB meningitis in up to 10% of patients who present with TB (from the rupture of a tuberculoma or blood-borne)
Always exclude cryptococcal meningitis by CSF microscopy (India ink stain)
Multidrug-resistant tuberculosis is rising (12-25% now!)
![Page 20: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/20.jpg)
Bacterial Infection: Strep pneumoniae, Neisseria Meningitis (Bacterial Meningitis)
Presenting Signs and Symptoms
Symptoms tend to present within one week of infection. May be preceded by a prodromal respiratory illness or sore throat.
- Fever - Vomiting
- Headache - Malaise
- Stiff neck - Irritability
- Photophobia - Drowsiness - Coma
![Page 21: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/21.jpg)
CSF Values
• leukocytosis • cerebrospinal fluid shows increased pressure • cell count (100 –10,000/mm3) • protein (>100 mg/dl) • decreased glucose (<40 mg/dl or <50% of the
simultaneous glucose blood level) • gram-stained smear of the spun sediment of the
CSF can reveal the etiologic agent
Diagnostics
![Page 22: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/22.jpg)
Management and Treatment
Penicillin (24 million units daily in divided doses every 2-3 hours)
or Ampicillin (12 gr daily in divided doses every 2-3 hours)
or Chloramphenicol (4 to 6 grams IV/day). Treatment should be continued for 10 to 14 days.
Crystalline penicillin 2-3 mega units and
chloramphenicol 500-750 mg every 6 hours for 10-14 days
![Page 23: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/23.jpg)
Unique featuresUnique features, , CaveatsCaveats
Often encountered during late stages of HIV disease. Prompt diagnosis and aggressive management and treatment ensure a quick recovery
![Page 24: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/24.jpg)
Fungal Infection: Cryptococcus neoformans
(cryptococcal meningo-encephalitis)
Presenting Signs and Symptoms
Presentation usually nonspecific for > 1 month. • Protracted headache and fever may be the only signs • Nausea, vomiting, and stiff neck may be absent and
focal neurological signs are uncommon early on. • Signs of raised ICP? • Extraneural symptoms: pneumonitis, pleural effusions,
skin lesions (rare) and retinitis • Fever, malaise, nuchal pain signify a worse prognosis • Imaging may be unrevealing: cryptococcomas are rare!
![Page 25: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/25.jpg)
Imaging?
LP !!!
CSF Values • Normal 20% • Culture (+) 95-100% • Protein 30-150/dl • WBC: 0-100 (monos) • Glucose decreased: 50-70mg/dl • Crypt Ag nearly 100% sensitive and specific
Diagnostics GMS stain
![Page 26: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/26.jpg)
Cryptoccocal meningitis: CSF
India ink examination positive in > 80%!!!
![Page 27: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/27.jpg)
Triple therapy effective (80% remission) but controversial (flucytosine only IV and is toxic)
![Page 28: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/28.jpg)
Unique featuresUnique features, , CaveatsCaveats
If untreated, it is slowly progressive and ultimately fatal
CSF is negative in approximately 60 % of cases after two weeks of successful therapy (< 4 weeks!)
Most common life-threatening fungal infection in HIV/AIDS patients. Also the most common cause of meningitis in patients with HIV/AIDS in Africa and Asia.
Occurs most often in patients with CD4<50
It is better prevented than treated
![Page 29: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/29.jpg)
Unique featuresUnique features, , CaveatsCaveats
Headache is secondary to fungal accumulation. Headache increases gradually over time and then follows a recurring pattern. It becomes harder to get rid of, and then becomes continuous. This is what the patient reports.
Requires lifelong suppressive treatment unless immune reconstitution occurs
If there is raised ICP, CSF drainage may become necessary. Steroids are useless here.
![Page 30: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/30.jpg)
Viral Infection: Cytomegalovirus (CMV) Resenting Signs and Symptoms
Fever ± delirium, lethargy, disorientation, malaise, headache most common. Stiff neck, photophobia, cranial nerve deficits less common.
Usually no focal neurological deficits
Other manifestations of disseminated CMV infection are rare (15 %), and can affect every organ. Pneumonia, esophageal ulcers, colitis and encephalitis are most frequently involved. Sinusitis and myelitis may also occur.
![Page 31: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/31.jpg)
![Page 32: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/32.jpg)
Retinal exam to check for changes. Consult an “HIV-experienced” ophthalmologist!
CMV retinitis, characterized by creamy yellow white, hemorrhagic, full thickness retinal opacification, which can cause visual loss and lead to blindness if untreated; patient may be asymptomatic or complain of floaters, diminished acuity or visual field defects. Retinal detachment if disease is extensive
CMV serology (IgG almost always positive, IgM variable) is usually not helpful.
CMV PCR or a blood test for pp65 antigen to detect antibodies against a CMV-specific phosphoprotein may be more useful. CMV retinitis or a recurrence is unlikely with a negative PCR or pp65 result.
Diagnostics
![Page 33: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/33.jpg)
Management and Treatment
HAART has dramatically improved prognosis. The previously required life-long daily infusions of ganciclovir or foscarnet via port, pumps and nursing service are luckily now a thing of the past. If there are relapses under oral valganciclovir, we recommend re-induction and maintenance therapy with foscarnet or possibly with cidofovir.
![Page 34: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/34.jpg)
Unique featuresUnique features, , caveatscaveats
Evolution occurs in less than 2 weeks Mainly in untreated patients when CD4<100
Although any part of the retina may be involved, there is a predilection for the posterior pole; involvement of the optic nerve head and macula region is common
Characteristically involves the retinal vessels which are always abnormal in areas involved by retinitis. There is minimal or no accompanying uveitis
Rare but devastating illness pre HAART. Treatment is very expensive and usually not available. CMV management needs special care. Therefore, early referral is essential – leads to blindness in 30% patients
![Page 35: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/35.jpg)
Viral Infection: Progressive mulltifocal leukoencephalopathy (PML)
Presenting Signs and Symptoms
Afebrile, alert, no headache Progressively impaired cognition & behaviour, speech, vision & motor function. Cranial nerve deficit and cortical blindness
JCV was named after the initials of the first patient in 1971 Seroprevalence is high (80 %); latent persistent infection must be assumed often. PML doesn’t always indicate the final stage of HIV infection
![Page 36: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/36.jpg)
CT may be normal or MRI may show some diffuse asymmetrical demyelination PCR of CSF (not sera!) for detection of JC virus
sensitivity 80%; specificity 90% (in good hands) Definitive
diagnosis
Diagnostics
Luxol fast blue EM
![Page 37: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/37.jpg)
ART can improve symptoms and prolong life. Foscarnet, interferon, immune stimulants, cytosine arabinoside and steroids failed!
Cidofovir and camptothecin being tested now The absolute priority should currently be to optimize ART
Management and Treatment
![Page 38: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/38.jpg)
Unique FeaturesUnique Features, , CaveatsCaveats CD4<100 (but possible with ~200 CD4 T cells)
PML is very rare in the general community, but 2nd most common nowadays in AIDS patients.
Evolution occurs over weeks to months. Always fatal in the pre-HAART era, prognosis is still poor.
peripheral enhancement observed after “immune reconstitution inflammatory syndrome - IRIS” (PML’s ‘inflammatory phase’).
Although lesions are huge, every PML starts small: very discrete, localized, solitary lesions do not exclude the diagnosis! Must differentiate from HHV-6 or HIV encephalopathies.
![Page 39: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/39.jpg)
Diagnosis of PML vs. MS
Typical of PML Clinical Tempo: Sub-acute Location: Sub-cortical, cerebellum
MRI Non-enhancing No mass effect Sub-cortical
CSF JCV DNA detectable
Differentiation vs. MS Clinical Tempo: Acute Location: ON, cord, and other localizations
MRI Gd enhancement Edema, mass effect Not only sub-cortical
CSF JCV DNA negative
![Page 40: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/40.jpg)
Features Suggestive of
• Behavioral and neuropsychological alteration
• Cortical signs and symptoms • Retrochiasmal visual deficits • Hemiparesis • Marked cerebellar findings • Gait/limb abnormalities
• Diplopia • Paraesthesiae • Paraparesis • Optic neuritis • Myelopathy
Typical Clinical Presentation
• Over weeks • Progressive
• Over hours to days • Normally stabilize • May resolve even
spontaneously
Evolution
• Sub-Acute • Acute Onset PML MS
Clinical Features of MS and PML
![Page 41: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/41.jpg)
Unique FeaturesUnique Features, , CaveatsCaveats
![Page 42: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/42.jpg)
Unique FeaturesUnique Features, , CaveatsCaveats
![Page 43: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/43.jpg)
Primary CNS lymphoma
Presenting Signs and Symptoms
Afebrile w/Headache, mental status, personality or behavioral changes over several weeks. Focal and multifocal neuro deficits, seizures.
Severely immunocompromised, constitutional symptoms may mask the actual problem.
![Page 44: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/44.jpg)
Cerebral lymphoma
![Page 45: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/45.jpg)
CT Scan MRI Peri-ventricular in one or more sites Prominent edema, irregular and solid on enhancement.
CSF: • Normal;—30-50% • Protein—10-150/ml • WBC—0-100 (monos) • Cytology positive in <5% • Suspect with negative toxo IgG or failure to
respond to empiric toxo treatment
Diagnostics
![Page 46: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/46.jpg)
Management and Treatment
There is no cytotoxic chemotherapy for this disease but a treatment attempt with IV MTX can be justified (3 g/m2 every 14 days with leucovorin rescue).
Irradiation (fractionated, 40 Gy total dose) can help some patients, but is considered palliative.
Dexamethasone 8 mg tid can help if raised ICP.
The decisive factor is the best possible immune reconstitution!
![Page 47: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/47.jpg)
Unique featuresUnique features, , CaveatsCaveats
PCNSL is rare in the general community, but affects up to 10% of AIDS patients
CD4 <50 Typical end-stage complication of HIV disease EBV-associated in almost 100 % of cases.
![Page 48: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/48.jpg)
HIV-associated dementia (HAD)
HIV encephalopathy (HIVE) AIDS dementia complex; AIDS dementia HIV-associated cognitive motor complex.
Presenting Signs and Symptoms
10-20% – decreased with HAART but now increasing due to increased life expectancy CD4 <200 Afebrile; general lethargy
Triad of cognitive, motor and behavioral dysfunction
![Page 49: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/49.jpg)
![Page 50: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/50.jpg)
CSF normal/decreased WBC w/ raised protein (OCB(+)!) subcortical dementia MMS not sensitive Memorial Sloan Kettering scale (Price 1988).
Diagnostics
![Page 51: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/51.jpg)
HIV-E Differential diagnoses
![Page 52: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/52.jpg)
Management and Treatment
Widely controversial and vastly unproven yet! Possible benefit from ARV agents that penetrate the CNS (zidovudine, lamivudine (high concentrations in ventricular CSF), nevirapine and indinavir)
Benefit of early AZT at higher dose for mild cases.
? selegeline, nimodipine, lexipafant and the antioxidant agent CPI-1189
![Page 53: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/53.jpg)
HIVHIV--associated associated myelopathy myelopathy ((HIVHIV--MM))
Clinically progressing with less prominent or no cognitive decline. Cervical/ thoracic w/ lipid-laden macrophages “vacuolar myelopathy” May be sub-clinical. Mainly with advanced immunosuppression Diagnosis: only non-specific findings Treatment: Early observations of significant improvement with zidovudine monotherapy were later confirmed with HAART.
![Page 54: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/54.jpg)
![Page 55: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/55.jpg)
Neurologic AIDS Research Consortium
Other Neurological Syndromes Reported with HCV
• Demyelinating myelitis• Cord biopsy
– Macrophages– Perivascular lymphocytes– Loss of myelin– Reactive gliosis– No HCV antigen
• ?Immune mediated myelitis
Grewal, J N Sci, 2004
![Page 56: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/56.jpg)
Painful Sensory and Motor Peripheral Neuropathies Presenting signs and symptoms
Burning pain and numbness in toes and feet, ankles, calves, fingers in more advanced cases Paraplegia Autonomic dysfunction Poor bowel/bladder control Dizziness secondary to postural hypotension Contact hypersensitivity in some cases Mild/moderate muscle tenderness Muscle weakness Later: Reduced pinprick/vibratory sensation; reduced or absent ankle/knee jerks Sweating
![Page 57: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/57.jpg)
EMG / NCT show predominantly axonal neuropathy CPK usually elevated CSF - look for cytomegalovirus or herpes simplex virus infections—lymphomatous infiltration Spinal fluid to determine etiology Serum B12 and TSH Quantitative sensory testing or thermal thresholds may be helpful
Diagnostics
![Page 58: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/58.jpg)
Management and Treatment
Exclude neurotoxic drugs, alcoholism, diabetes, B12 deficiency, thyroid problems and treat underlying causes if known.
Discontinue presumed neurotoxic medication (d4T, ddC, ddI, possibly also 3TC) often resolves only very slowly, therefore change treatment quickly!
Severe, progressive muscular weakness (d4T, ddI)
Provide proper nutrition and vitamin supplements
![Page 59: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/59.jpg)
![Page 60: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/60.jpg)
![Page 61: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/61.jpg)
Treatments for neuropathies
![Page 62: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/62.jpg)
HIV myopathies
• Myalgia, fatigue and raised CK are frequently found in HIV infection. • The diagnosis of probable myopathy requires weakness, muscle atrophy or myopathic features demonstrated by electromyography. • Treat w/ Prednisone or IvIg • Stop AZT
![Page 63: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/63.jpg)
Neurosyphilis
Presenting Signs and Symptoms Can be asymptomatic
Headache, fever, photophobia, meningismus ± seizures, focal findings, cranial nerve palsies
Tabes dorsalis—sharp pains, parasthesias, decreased DTRs, loss of pupil response
General paresis— memory loss, dementia, personality changes, loss of pupil response
Meningovascular strokes, myelitis Ocular syphilis—iritis, uveitis, optic neuritis
![Page 64: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/64.jpg)
CT Scan/MRI: Aseptic meningitis—may show meningeal enhancement General paresis—cortical atrophy, sometimes with infarcts
Meningovascular syphilis—deep strokes. Dementia?
CSF: Protein—45-200/ml WBCs—5-100 (monos) VDRL positive—sensitivity 65%; specificity 100% positive Serum VDRL and FTA-ABS are clue in >90%; false neg serum VDRL in 5-10% with tabes dorsalis or general paresis
Definitive diagnosisDefinitive diagnosis: : positive CSFpositive CSF, , VDRL VDRL ((found in found in 6060--70%70%))
Diagnostics
![Page 65: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/65.jpg)
Management and Treatment
Give Aq penicillin G, 18-24 mil units/day x 10-14 days
Follow-up VDRL every 6 months until negative
Indications to re-treat: • CSF WBC fails to decrease at 6 months or CSF still
abnormal at 2 years • Persisting signs and symptoms of inflammatory
response at 3 months • Four-fold increase in CSF VDRL at 6 months
Failure of CSF VDRL of 1:16 to decrease by two-fold by 2 months or four-fold by 12 months
![Page 66: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/66.jpg)
Unique featuresUnique features, , CaveatsCaveats
0.5% of all HIV/AIDS patients
Most common forms in HIV-infected persons are ocular, meningeal, and meningovascular
Some evidence that syphilis progresses more rapidly in the context of HIV infection, so that complications may occur at an unusually early phase.
Recommended that syphilis testing be offered to all in high prevalence areas because it is treatable in early stages, and has an accelerated course in HIV.
CD4<350
Lancet InfectLancet Infect Dis Dis 20042004; ; 44: : 456456––6666
Syphilis and HIVSyphilis and HIV: : a dangerous combinationa dangerous combination.. W A Lynn and SW A Lynn and S Lightman Lightman
![Page 67: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/67.jpg)
Last slides after this brief
announcement ☺
http://www.unaids.org/
![Page 68: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/68.jpg)
42
HIV Risk Factors
“Unprotected” sexual contact, since 1978Any “STD”, HPV/Pap, OCPs…
“Recreational” blood exposureIVDU, tattoos, cocaine straws, etc.
Receipt of tissue or blood productsRisk 1:60,000 / 1985 → 1:675,000 / 1996 (USA)
“PARTNER” with above risksPerson from high prevalence groupNote “6-month” negative window
![Page 69: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/69.jpg)
42
HIV Risk Factors
“Unprotected” sexual contact, since 1978Any “STD”, HPV/Pap, OCPs…
“Recreational” blood exposureIVDU, tattoos, cocaine straws, etc.
Receipt of tissue or blood productsRisk 1:60,000 / 1985 → 1:675,000 / 1996 (USA)
“PARTNER” with above risksPerson from high prevalence groupNote “6-month” negative window
![Page 70: NEURO HIV/AIDS Objectives](https://reader034.fdocuments.net/reader034/viewer/2022051411/54660207af795969338b5069/html5/thumbnails/70.jpg)
43
Sexual Risk Assessment“Have you…?”
? Ever had sex since 1978 ?? Used condoms 100% ?
? Used oral contraceptives ?? Ever been pregnant ?
? Ever had:? A sexually transmitted infection ?? An abnormal Pap smear ?
? Had sex with men, women or both ?? Had sex vaginally, orally or rectally ?
Do you know the above for all of your partners ???